Can bilirubin nanomedicine become a hope for the management of COVID-19?

Simple item page
dc.contributor.authorKhurana, Isha
dc.contributor.authorAllawadhi, Prince
dc.contributor.authorKhurana, Amit
dc.contributor.authorSrivastava, Amit Kumar
dc.contributor.authorNavik, Umashanker
dc.contributor.authorBanothu, Anil Kumar
dc.contributor.authorBharani, Kala Kumar
dc.date.accessioned2024-01-21T10:54:57Z
dc.date.accessioned2024-08-14T07:44:23Z
dc.date.available2024-01-21T10:54:57Z
dc.date.available2024-08-14T07:44:23Z
dc.date.issued2021-02-15T00:00:00
dc.description.abstractBilirubin has been proven to possess significant anti-inflammatory, antioxidant and antiviral activities. Recently, it has been postulated as a metabolic hormone. Further, moderately higher levels of bilirubin are positively associated with reduced risk of cardiovascular diseases, diabetes, metabolic syndrome and obesity. However, due to poor solubility the therapeutic delivery of bilirubin remains a challenge. Nanotechnology offers unique advantages which may be exploited for improved delivery of bilirubin to the target organ with reduced risk of systemic toxicity. Herein, we postulate the use of intravenous administration or inhalational delivery of bilirubin nanomedicine (BNM) to combat systemic dysfunctions associated with COVID-19, owing to the remarkable preclinical efficacy and optimistic results of various clinical studies of bilirubin in non-communicable disorders. BNM may be used to harness the proven preclinical pharmacological efficacy of bilirubin against COVID-19 related systemic complications. � 2021 Elsevier Ltden_US
dc.identifier.doi10.1016/j.mehy.2021.110534
dc.identifier.issn3069877
dc.identifier.urihttp://10.2.3.109/handle/32116/4288
dc.identifier.urlhttps://linkinghub.elsevier.com/retrieve/pii/S0306987721000529
dc.language.isoen_USen_US
dc.publisherChurchill Livingstoneen_US
dc.subjectAnti-inflammatoryen_US
dc.subjectAntioxidanten_US
dc.subjectBilirubinen_US
dc.subjectBiliverdinen_US
dc.subjectCOVID-19en_US
dc.subjectNanomedicineen_US
dc.titleCan bilirubin nanomedicine become a hope for the management of COVID-19?en_US
dc.title.journalMedical Hypothesesen_US
dc.typeArticleen_US
dc.type.accesstypeOpen Accessen_US

Files

Collections

Pharmacology - Research Publications